Dermatology Therapeutics Drug Development Pipeline Review, 2017
 |
| Dermatology Therapeutics Drug |
Albany, New York, Mar 15, 2017
"Dermatology
Therapeutics Drug Development Pipeline Review, 2017"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Dermatological
conditions are one of the most common types of disorders worldwide,
and approximately one-third of the US population suffers from at
least one active skin condition. For the past decades, the majority
of the dermatology market has remained saturated with established and
generic products. However, the clinical and commercial success of
biologics in the treatment of psoriasis, as well as advancements in
the understanding of the disease pathways of many dermatological
conditions, have led to a renewed interest from pharmaceutical
companies in the dermatology market, and subsequently the emergence
of an innovative pipeline.
There
are over 800 products in active development in the dermatology
therapy area, with the majority of products being small molecules.
Biologics represent approximately 40% of the pipeline, despite the
fact that this molecule type represents only a small fraction of the
marketed products landscape.
Overall, the dermatology pipeline is highly
innovative, owing to the advancements in the understanding of the
disease pathways of many skin disorders. The number of strong
late-stage products and substantial early-stage segment of this
active and diverse pipeline are strong indicators of long-term growth
in this market.
The report provides comprehensive information on
the pipeline development landscape for is Acne vulgaris, Psoriasis
and Atopic dermatitis, from Discovery through to the Pre-Registration
stage. This includes an analysis of products by stage of development,
molecular target, mechanism of action (MoA), route of administration
(RoA) and molecule type. A list of all products in development is
provided, including dormant and discontinued projects. Finally, the
report provides an overview of key players involved in the
development of products in this area, and outlines recent updates and
press releases in the field.
** Scope
- Which companies are the most active within the pipeline for dermatology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
** Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Comments
Post a Comment